In June, a study supported by the National Cancer Institute found that for people with HIV, early treatment of precancerous anal lesions caused by human papillomavirus (HPV) can cut rates of anal cancer incidence by more than half. These findings from the Anal Cancer/HSIL Outcomes Research (ANCHOR) study are creating secondary prevention options for those at risk for anal cancer who have not received the HPV vaccine. We look into the history of the study and what its work means for those at risk for anal cancer.
Cancer HealthCast
47m listen
An Intersectional Look at Anal Cancer and HIV
NCI’s ANCHOR study discovered that early treatment of precancerous lesions can cut anal cancer rates by more than half in people with HIV.
-
Dr. Joel Palefsky Professor of Medicine University of California San Francisco
-
Dr. Robert Yarchoan Director, Office of HIV and AIDS Malignancy NCI
Related Content
-
Cancer HealthCast: This Unique Network Closes Research Gaps in Cancer Genomics
Dr. Leah Mechanic, Program Director at NCI and Dr. Bettina Drake, Professor at Washington University School of Medicine
24m listen -
HealthCast: Indian Health Service's Modernization Journey Means Replacing HHS’s Oldest Legacy System
Indian Health Service CIO Mitchell Thornbrugh joins HealthCast to talk about ways that IHS is progressing in its modernization program and the need for a patient-centered, human-centered approach to care.
26m listen -
CyberCast: CISA Task Force Prioritizes Managing Critical Infrastructure Risks, Countering Future Threats
The National Risk Management Center creates a unique task force designed to mitigate supply chain vulnerabilities, identify emerging threats and boost resiliency.
26m listen -
DOD Tackles Talent Management for the AI Age
Angela Cough, Chief of Digital Talent Management Office, DOD CDAO
28m listen